Tau protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Tau protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Tau protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Tau protein inhibitors: Overview
Tau proteins are proteins that perform the function of stabilizing microtubules. These proteins are abundant in nerve cells and are present to a much lesser degree in oligodendrocytes and astrocytes. When Tau proteins become defective and fail to adequately stabilize microtubules, pathologies of the nervous system can develop such as Alzheimer’s disease.
Function - Tau proteins are mainly active in the distal portions of axons where they stabilize microtubules as well as providing flexibility. The proteins work together with a globular protein called tubulin to stabilize microtubules and aid the assembly of tubulin in the microtubules. Tau proteins achieve their control of microtubule stability through isoforms and phosphorylation. Hyperphosphorylation of tau proteins can cause the helical and straight filaments to tangle (referred to as neurofibrillary tangles). These tangles contribute to the pathology of Alzheimer’s disease.
Tau protein inhibitors - Alzheimer disease is characterized by pathological aggregation of two proteins, tau and A?-amyloid, both of which are considered to be toxic to neurons. Recent advances have shown small molecule inhibitors of protein aggregation with emphasis on tau, with activities mediated by the direct interference of self-assembly. The inhibitors can be clustered in several compound classes according to their chemical structure, with subsequent description of the structure–activity relationships, showing that hydrophobic interactions are prevailing.
Tau protein inhibitors Emerging Drugs Chapters
This segment of the Tau protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tau protein inhibitors Emerging Drugs
Further product details are provided in the report……..
Tau protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Tau protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Tau protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau protein inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Tau protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Tau protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Tau protein inhibitors: Overview
Tau proteins are proteins that perform the function of stabilizing microtubules. These proteins are abundant in nerve cells and are present to a much lesser degree in oligodendrocytes and astrocytes. When Tau proteins become defective and fail to adequately stabilize microtubules, pathologies of the nervous system can develop such as Alzheimer’s disease.
Function - Tau proteins are mainly active in the distal portions of axons where they stabilize microtubules as well as providing flexibility. The proteins work together with a globular protein called tubulin to stabilize microtubules and aid the assembly of tubulin in the microtubules. Tau proteins achieve their control of microtubule stability through isoforms and phosphorylation. Hyperphosphorylation of tau proteins can cause the helical and straight filaments to tangle (referred to as neurofibrillary tangles). These tangles contribute to the pathology of Alzheimer’s disease.
Tau protein inhibitors - Alzheimer disease is characterized by pathological aggregation of two proteins, tau and A?-amyloid, both of which are considered to be toxic to neurons. Recent advances have shown small molecule inhibitors of protein aggregation with emphasis on tau, with activities mediated by the direct interference of self-assembly. The inhibitors can be clustered in several compound classes according to their chemical structure, with subsequent description of the structure–activity relationships, showing that hydrophobic interactions are prevailing.
Tau protein inhibitors Emerging Drugs Chapters
This segment of the Tau protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tau protein inhibitors Emerging Drugs
- R-phenserine: Annovis Bio
- Bepranemab: UCB
- Hydromethylthionine mesylate (TRx-0237): TauRx Pharmaceuticals
Further product details are provided in the report……..
Tau protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Tau protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Tau protein inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Tau protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau protein inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Tau protein inhibitors R&D. The therapies under development are focused on novel approaches for Tau protein inhibitors.
- Tau protein inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Tau protein inhibitors drugs?
- How many Tau protein inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Tau protein inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tau protein inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Tau protein inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Annovis Bio
- UCB Biopharma
- TauRx Pharmaceuticals
- Voyager Therapeutics
- Oligomerix
- APRINOIA Therapeutics
- Sangamo Therapeutics
- AC Immune
- Eli Lilly and Company
- Denali Therapeutics Inc
- Takeda
- TAU BIO-LOGIC
- VITRUVIAN BioMedical
- BeyondBio
- DTx Pharma
- Eisai Co Ltd
- reMYND
- Dong-A ST
- R-phenserine
- Bepranemab
- Hydromethylthionine mesylate (TRx-0237)
- Vectorized tau antibodies
- ST 501
- ACI 3024
- AT 8 antibody
- ATV:BACE1/Tau
- TBL 100
- YM 7555
- BEY-2153
- MSUT2 programme
- E 2814
- ReS19 T
- NB 02
Introduction
Executive Summary
Tau protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Tau protein inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Tau protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Tau protein inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
TRx-0237: TauRx Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
R-phenserine : Annovis Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Bepranemab: UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NB 02: Dong-A ST
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Tau protein inhibitors Key Companies
Tau protein inhibitors Key Products
Tau protein inhibitors- Unmet Needs
Tau protein inhibitors- Market Drivers and Barriers
Tau protein inhibitors- Future Perspectives and Conclusion
Tau protein inhibitors Analyst Views
Tau protein inhibitors Key Companies
Appendix
Executive Summary
Tau protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Tau protein inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Tau protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Tau protein inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
TRx-0237: TauRx Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
R-phenserine : Annovis Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Bepranemab: UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NB 02: Dong-A ST
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Tau protein inhibitors Key Companies
Tau protein inhibitors Key Products
Tau protein inhibitors- Unmet Needs
Tau protein inhibitors- Market Drivers and Barriers
Tau protein inhibitors- Future Perspectives and Conclusion
Tau protein inhibitors Analyst Views
Tau protein inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Tau protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Tau protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Tau protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Tau protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
